Compare Frontline Plc Ordinary Shares (FRO) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Frontline Plc Ordinary Shares vs Organon & Co. Common Stock — how do they compare? Frontline Plc Ordinary Shares trades at $55.16 (market cap $13.14B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Frontline Plc Ordinary Shares is far larger — about 3.6× Organon & Co. Common Stock's market cap, and Frontline Plc Ordinary Shares pays the higher dividend (9.11%). Which is the better fit depends on your goals — on Pluang, investors hold Frontline Plc Ordinary Shares for 1 Days and Organon & Co. Common Stock for 0 Days on average.
| FRO | OGN | |
|---|---|---|
Market Cap | $13.14B | $3.62B |
Volume | 3,351,547 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $59.19 | $13.81 |
52-Week Low | $20.58 | $5.70 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $15.26B | $11.04B |
Dividend Yield | 9.11% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Frontline (FRO) trades at $59.04, down 0.25% on the day, but maintains a strong technical and fundamental position. The stock is near its 52-week high, supported by bullish moving averages and robust earnings, with Q2 2026 EPS beating estimates at $2.96. Revenue and profitability have surged, with 2026 net income margin projected at 54.75%. Recent news highlights a special dividend declaration and institutional buying interest.
The outlook for FRO is positive, driven by record earnings and favorable shipping market dynamics. Investment opportunities include strong cash flow generation and shareholder returns, but risks involve exposure to volatile freight rates and geopolitical tensions affecting global trade. Analyst sentiment is mixed, with a 'Hold' consensus suggesting cautious optimism amid near-term highs.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Frontline Plc Ordinary Shares
Frontline operates a fleet of oil tankers that transport crude oil by sea. Its vessels serve global energy trading routes.
Read more on FRO →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
